PPR-117 - Risk of severe exacerbation associated with Gabapentinoid use in patients with Chronic Obstructive Pulmonary Disease: A population-based cohort study

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: PPR-117
• By: OLAOYE, Omotayo (Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Canada)
• Co-author(s): Ms Omotayo Olaoye (Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada / Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada)
  Ms. Sophie Dell'Aniello (Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada)
  Dr. Pierre Ernst (Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada / Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada / Department of Medicine, McGill University, Montreal, Canada)
  Prof. Samy Suissa (Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada / Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada / Department of Medicine, McGill University, Montreal, Canada)
  Prof. Christel Renoux (Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada / Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada / Department of Medicine, McGill University, Montreal, Canada / Department of Neurology and Neurosurgery, McGill University, Montreal, Canada)
  
• Abstract:

  Background
  Gabapentinoids (gabapentin and pregabalin) have been linked to adverse respiratory events, with particular concern for individuals with risk factors such as chronic obstructive pulmonary disease (COPD). However, real-world evidence on the risk of adverse respiratory outcomes associated with gabapentinoid use in this population remains..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login